Integrum AB Series B

INTEG-B · Nasdaq Stockholm · Healthcare

8.96SEK −0.6%last day

Price as of 2 October 2026

The price over the past year, with dividends: −37.3%

Performance

1 month

−2.6%

1 year

−37.3%

3 years, per year

−31.8%

5 years, per year

−35.7%

Largest fall, 3 years

−88.8%

Below the peak now

−91.2%

Volatility, 1 year

57.1%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

1.3

Dividend yield

0.0%

Return on equity

−20.4%

Net margin

−36.3%

Market value

24 m USD

Quality, value and trend

Where Integrum stands against every Nordic stock today. 100 is best.

Quality41

Profitability and a sound balance sheet over time. Better than 41% of Nordic stocks.

Value34

The price measured against earnings, assets and cash flow. Better than 34% of Nordic stocks.

Trend56

The price development over the past year. Better than 56% of Nordic stocks.

Combined35

Quality, value and trend together. Better than 35% of Nordic stocks.

About Integrum

Integrum AB Series B is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 33 employees.

Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoiding bone fractures from accidental loads. It also provides Neuromotus, a technology that is used for therapy to reduce phantom limb pain after an amputation. It sells its implant systems to hospitals, clinics, and orthopedists worldwide.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis